Literature DB >> 20665986

Clinical study of Acrysof IQ aspheric intraocular lenses.

Min Luo1, Jing Ji, Chun Zhao, Xianqun Fan.   

Abstract

PURPOSE: To determine whether implantation of anaspheric intraocular lens (SN 60 WF Alcon) results in reduced spherical aberration and improved contrast sensitivity after cataract surgery.
METHODS: Randomized, prospective study. 260 patients/eyes were randomized to receive two intraocular lens types: Alcon Acrysof Natural (136 eyes) and Acrysof IQ (124 eyes). Quality of vision was measured by visual acuity and contrast sensitivity under mesopic and photopic conditions. Ocular aberrations for 4.0- and 6.0-mm pupil were measured with Allegretto Wavelight Analyzer. All ophthalmologic were performed 7, 30 and 90 days postoperatively. Visual function index (VF-14) questionnaires for cataract symptoms were performed 90 days after surgery by all the patients.
RESULTS: After 90 days, all eyes had mean postoperative best spectacle-corrected visual acuity 0.75. Eyes with the Acrysof IQ had significantly higher contrast sensitivity than eyes with the Acrysof Natural at high and middle spatial frequencies. A significant reduction in spherical aberration after Acrysof IQ implantation was achieved. The Acrysof IQ also had lower values of high-order aberration with 4.0- and 6.0-mm pupil when compared with the AcrySof Natural.
CONCLUSION: Results show the aspheric Acrysof IQ induced significantly less high-order aberration and spherical aberration compared with the Acrysof Natural. Contrast sensitivity revealed better values with the Acrysof IQ intraocular lens.

Entities:  

Mesh:

Year:  2010        PMID: 20665986     DOI: 10.1111/j.1442-9071.2010.02253.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  1 in total

1.  Visual performance of Acrysof ReSTOR compared with a monofocal intraocular lens following implantation in cataract surgery.

Authors:  Jing Ji; Xiaolin Huang; Xianqun Fan; Min Luo
Journal:  Exp Ther Med       Date:  2012-10-10       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.